The 4 Arguments You Will Hear Against Drug Price Negotiation

As the Biden administration begins the process of negotiating prices for 10 costly drugs on behalf of Medicare and its beneficiaries as authorized in last year’s Inflation Reduction Act, KFF Executive Vice President for Health Policy Larry Levitt probes some likely arguments against it in this op-ed column in The New York Times. The column also examines the policy and political implications of the debate and pending legal challenges.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.